Broker heavyweight Deutsche is upbeat on drugs giant GlaxoSmithKline (LON:GSK) on Friday and has punted up the target price to 1,500p from 1,450p.
It comes after what the broker calls a "convincing" set of third quarter results.
"Strong performances from Tivicay/Triumeq and Vaccines, along with the beginnings of delivery on margin improvements, convince us that guidance for 2015 is a low hurdle," said the broker, which has upgraded its forecasts.
At a research and development day on November 3 the broker said it will be looking for "evidence of a progress of the early pipeline to reassure over longer term sustainability of the expected near-term earnings recovery".
"Updates on HIV lifecycle management will be important given competitor Gilead’s decision to progress an unboosted novel integrase inhibitor into late-stage development."
The broker repeated a 'hold' stance on the shares.
Gold miner Centamin (LON:CEY) is another company receiving an analyst upgrade today.
Japanese broker Nomura lifts the stock to 'neutral' from 'reduce' and has a target price of 60p.
Following quarterly results yesterday, JP Morgan Cazenove looks at banking group Barclays (LON:BARC) and drops the price target to 300p from 320p but has an 'overweight' stance.
It says the bank' core business remains undervalued and that there is still upside from non-core still ahead.
It cuts pre-tax estimates for full year 2016 by 2% but keeps its 2017 pre-tax profit estimates unchanged.
Barclays yesterday unveiled a 29% drop in third quarter profit.
The same broker upgrades UK engineer Meggitt (LON:MGGT) to 'neutral' from 'underweight' after yesterday's profit warning.
Shares dropped 24% yesterday after it warned that annual profit would be below forecasts and that it would cut about 300 jobs.
The broker notes that Meggitt does have "some attractive niches and above-average margins", offset by the broker's concerns over current headwinds and accounting.
Its price target continues to incorporate a 7.5% premium to fair value for potential M&A (mergers and acquisitions), namely the broker assumes a 25% probability that Meggitt could be acquired for a 30% premium.
To small caps, and broker VSA looked at gold recovery specialist Goldplat (LON:GDP), which yesterday announced a trading update for FY Q1 2015, which confirmed the view that a turnaround in FY 2016 was well underway.
In FY Q1 2016 GDP produced 9,581oz gold, sold 8,680oz while 1,608oz were transferred to clients as metal transfers.
"We maintain our full year forecast of 31.5koz gold production and 35koz sales as the backlog of stock is reduced," it said.
The broker repeated its target price of 6.1 pence a share and 'buy' stance.
Broker Sanlam picks out the positives after Africa-focused low cost carrier fastjet (LON:FJET) announced yesterday its debut first flight in Zimbabwe - its second base in Africa.
The successful initial flight set-off from Harare and landed in Victoria Falls, before returning.
"..fastjet Zimbabwe will initially fly this route three times a week on Wednesdays, Fridays, and Sundays, with more flights being added as demand increases," noted the City broker, which repeated a 'buy' stance.